Application and role of fibrates in treatment of primary biliary cholangitis and related mechanisms / 临床肝胆病杂志

ABSTRACT

Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is the only safe and effective drug for PBC approved by FDA. To date, there is no unified therapeutic regimen for patients with suboptimal response to UDCA. Fibrates are a class of synthesized ligands of peroxisome proliferator-activated receptors, and recent studies have shown that fibrates may have anticholestatic, anti-inflammatory, and antifibrotic effects. The article reviews the application of fibrates in the treatment of PBC and possible mechanisms.